Clinical Report: Functional Outcomes of Current Dry AMD Therapies
Overview
Revise to specify the uncertainty in the correlation between anatomical improvements and functional outcomes.
Background
Age-related macular degeneration (AMD) is a significant cause of blindness in the elderly, with projections indicating a rise in prevalence due to an aging population. The recent FDA approvals of pegcetacoplan and avacincaptad pegol mark a critical development in the management of geographic atrophy (GA) associated with dry AMD. Understanding the functional outcomes of these therapies is essential for optimizing patient care and treatment decisions.
Data Highlights
| Study | Drug | GA Growth Reduction | Time Frame |
|---|---|---|---|
| OAKS | Pegcetacoplan | 21% | 12 months |
| GATHER1 | Avacincaptad pegol | 27% | 12 months |
Key Findings
- Pegcetacoplan significantly slowed GA lesion growth by 21% compared to sham treatment in the OAKS trial.
- Avacincaptad pegol reduced mean GA growth by 27% at 12 months in the GATHER1 trial.
- Despite anatomical improvements, significant differences in visual function endpoints were not observed in the OAKS trial.
- The location and size of GA lesions may influence the functional benefits of treatments.
- Ongoing studies, such as the GALE extension study, are assessing the long-term efficacy of pegcetacoplan.
Clinical Implications
Clinicians should consider both anatomical and functional outcomes when evaluating treatment options for patients with dry AMD. Understanding the specific characteristics of GA lesions can guide treatment decisions and patient counseling regarding expected visual function outcomes.
Conclusion
While pegcetacoplan and avacincaptad pegol represent significant advancements in the treatment of dry AMD, further research is needed to clarify their impact on visual function and to optimize patient management strategies.
References
- Retinal Physician, Early-phase Drugs in Development for Dry AMD, 2022 -- Promising candidates are numerous.
- Retinal Physician, Oral Drug Pipeline for Retinal Disease, 2022 -- Systemic options could reduce patient burden.
- Contact Lens Spectrum, treatment plan, 2002 -- Contemporary AMD Management Strategies, Part II.
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University, 2025.
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed.
- Retinal Physician — Gene Therapy for Dry AMD
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
- Photobiomodulation for Age-Related Macular Degeneration | Ophthalmology | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.